High expression of AGR2 in lung cancer is predictive of poor survival

Alavi, Mohammed; Mah, Vei; Maresh, Erin L.; Bagryanova, Lora; Horvath, Steve; Goodglick, Lee; Liu, Alvin Y.

doi:10.1186/s12885-015-1658-2

Cited by 47 publications

(41 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…clearly up-regulated in LUSC, entailing a promising marker to discriminate the two lung cancer types. Another interesting candidate is AGR2, which has been associated with lung cancer, as a prognostic marker [98][99][100]. Our results point to an up-regulation of AGR2 in LUAD, consistently with the findings in literature and down-regulation in LUSC.…”

Section: Candidate Genes In Lung Cancer and Other Cancer Typessupporting

confidence: 90%

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

et al. 2019

View full text Add to dashboard Cite

Background: Genomic initiatives such as The Cancer Genome Atlas (TCGA) contain data from-omics profiling of thousands of tumor samples, which may be used to decipher cancer signaling, and related alterations. Managing and analyzing data from large-scale projects, such as TCGA, is a demanding task. It is difficult to dissect the high complexity hidden in genomic data and to account for inter-tumor heterogeneity adequately. Methods: In this study, we used a robust statistical framework along with the integration of diverse bioinformatic tools to analyze next-generation sequencing data from more than 1000 patients from two different lung cancer subtypes, i.e., the lung adenocarcinoma (LUAD) and the squamous cell carcinoma (LUSC). Results: We used the gene expression data to identify co-expression modules and differentially expressed genes to discriminate between LUAD and LUSC. We identified a group of genes which could act as specific oncogenes or tumor suppressor genes in one of the two lung cancer types, along with two dual role genes. Our results have been validated against other transcriptomics data of lung cancer patients. Conclusions: Our integrative approach allowed us to identify two key features: a substantial up-regulation of genes involved in O-glycosylation of mucins in LUAD, and a compromised immune response in LUSC. The immune-profile associated with LUSC might be linked to the activation of three oncogenic pathways, which promote the evasion of the antitumor immune response. Collectively, our results provide new future directions for the design of target therapies in lung cancer.

show abstract

Section: Candidate Genes In Lung Cancer and Other Cancer Typessupporting

confidence: 90%

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

et al. 2019

View full text Add to dashboard Cite

show abstract

“…19 Recently, anterior gradient protein-2 (AGR2), an androgen-regulated gene, has been identified as an oncogene and generally overexpressed in various cancers. [20][21][22][23] AGR2 promotes the metastasis of breast cancer cells. 21 Besides, High AGR2 expression has been reported to show lower overall survival of CRC patients.…”

Section: Discussionmentioning

confidence: 99%

“…22 Moreover, AGR2 expression has been observed relatively high in prostate cancer and lung cancer. 20,23 It has been reported that AGR2 is a direct target of miR-342-3p. 13 In our study, LINC00460 was proved to mainly distribute in the cytoplasm, thus regulating the post-transcription of miRNAs.…”

Section: Discussionmentioning

confidence: 99%

<p>Long Noncoding RNA LINC00460 Promotes Hepatocellular Carcinoma Progression via Regulation of miR-342-3p/AGR2 Axis</p>

Yang¹,

Li²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide. LINC00460, a novel long non-coding RNA (lncRNA), was recently confirmed as an oncogene in various cancers. However, the biological function and underlying mechanism of LINC00460 in HCC is largely obscure. Methods: Fifty pairs of tumor tissue and adjacent normal tissues from HCC patients, as well as six HCC cell lines and a normal human hepatic epithelial cell line were subjected to qRT-PCR assay to evaluate the expression levels of LINC00460. CCK-8 assays were used to detect the proliferation of HCC cells. Transwell assay was used to measure the migration and invasion abilities of HCC cells. RNA pull-down and luciferase assays were performed to verify the direct interaction between LINC00460 and miR-342-3p. A xenograft model of HCC was established to validate the in vivo function of LINC00460 in HCC progression. Results: We firstly detected LINC00460 expression was significantly upregulated in both HCC tumor tissues and cell lines. The upregulation of LINC00460 was positively associated with HCC progression. Functionally, LINC00460 facilitated HCC cell proliferation, migration, and invasion capacities, which due to that LINC00460 could physically bind to and repress miR-342-3p to elevate the expression of AGR2. Conclusion: Our data firstly reveal the clinical relevance, biological function, and regulatory mechanism of LINC00460 in HCC development. LINC00460 promotes HCC progression by elevating AGR2 expression via sponging miR-342-3p, providing a promising therapeutic target for HCC treatment.

show abstract

“…AGR2 expression was shown to be significantly increased in HER2 positive breast tumors [147]. High levels of AGR2 were also associated with cell dissemination of pancreatic carcinoma [148] and with poor prognosis of lung cancer [149]. Worth of note, this protein appears highly represented in the tumor tissues (when present) and almost absent in the normal ones.…”

Section: Anterior Gradient Protein 2 Homolog Agr2 (Agr2)mentioning

confidence: 97%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Pucci‐Minafra¹,

Cara²,

Musso³

et al. 2017

Preprint

View full text Add to dashboard Cite

Abstract:The present investigation has been conducted on one hundred tissue fragments of breast cancer, collected and immediately cryopreserved following the surgical resection. The fragments were selected from patients with invasive ductal carcinoma of the breast, the most common and potentially aggressive type of mammary cancer, with the objective to increase the knowledge of breast cancer molecular markers, useful for diagnostic and prognostic categorization of patients, in assessing postsurgical therapeutic regimes. The proteomic screening, by 2D-IPG and mass spectrometry, allowed us to identify two main classes of protein clusters: proteins expressed ubiquitously at high levels in all patients, and proteins expressed sporadically among the same patients. Within the group of ubiquitous proteins, glycolytic enzymes and proteins with anti-apoptotic activity were predominant. Among the sporadic ones, proteins involved in cell motility, molecular chaperones and proteins involved in the detoxification appeared prevalent. The data of the present study indicates that the primary tumor growth is generally supported by two concurrent pathways: the inhibition of apoptosis and the stimulation of cellular proliferation. The second phase of the evolution of the tumor can be prematurely scheduled by the occasional presence of proteins involved in cell motility and in the defenses of the oxidative stress. To our knowledge this report on large-scales proteomics of breast cancer is currently a unique approach in the literature that offers the opportunity to evaluate the presence and recurrence of proteins to be used as prognostic indicators and susceptibility to metastasis in patients operated on for invasive ductal carcinoma of the breast.

show abstract

High expression of AGR2 in lung cancer is predictive of poor survival

Cited by 47 publications

References 38 publications

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

<p>Long Noncoding RNA LINC00460 Promotes Hepatocellular Carcinoma Progression via Regulation of miR-342-3p/AGR2 Axis</p>

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Contact Info

Product

Resources

About